38 results on '"B. Bauduceau"'
Search Results
2. Collaborateurs de la présente édition
- Author
-
N. Nabholz, C. Ciangura, M. Morena, R. Roussel, J.-L. Richard, A. Grimaldi, C. Colette, J.-P. Cristol, I. Banu, G. Lagger, B. Canaud, P. Valensi, G. Ha Van, J.-J. Robert, A. Wojtusciszyn, O. Dupuy, L. Monnier, S. Chiheb, F. Bonnet, S. Jacqueminet, A. Golay, A. Scheen, H. Leray-Moragues, E. Renard, E. Bousquet, C. Brunet, M. Chambouleyron, A. El Azrak, S. Schuldiner, M. Baudot, A. Fontbonne, L. Bordier, M. Marre, F. Galtier, E. Cosson, C. Sachon, J. Bringer, A. Lasserre-Moutet, C. Serny, A. Giordan, B. Vialettes, B. Vergès, J.-L. Schlienger, A. Hartemann, I. Aubry, F. Travert, S. Halimi, M. Piperno, D. Rochd, B. Bauduceau, J.-F. Blicklé, and P.-J. Guillausseau
- Published
- 2019
3. Collaborateurs de la précédente édition
- Author
-
G. Ha Van, A. Hartemann, Paul Valensi, I. Aubry-Quénet, S. Chiheb, H. Mayaudon, P J Guillausseau, C. Sachon, A. Grimaldi, L. Bordier, M. Baudot, H. Leray-Moragues, André Giordan, B. Vialettes, S. Renaud, B. Canaud, L. Monnier, F. Galtier, S. Schuldiner, J.-J. Robert, M. Halbron, Jean-Louis Schlienger, R. Roussel, A. Lasserre Moutet, Grégoire Lagger, O. Dupuy, Alain Golay, B. Vergès, A. Fontbonne, C. Brunet, C. Ciangura, J. Bringer, S. Halimi, S. Allieu-Amara, J.-L. Richard, I. Banu, J.-F. Blickle, E. Cosson, E. Bousquet, M. Marre, L. Chenine, Monique Chambouleyron, F. Travert, É. Renard, C. Colette, M. Piperno, E. Lecornet-Sokol, S. Jacqueminet, A. Wojtusciszyn, and B. Bauduceau
- Published
- 2019
4. Désordres cliniques et biologiques associés
- Author
-
L. Bordier, H. Mayaudon, O. Dupuy, and B. Bauduceau
- Subjects
business.industry ,Medicine ,business - Published
- 2014
5. Thérapeutique des désordres associés
- Author
-
L. Bordier, B. Bauduceau, H. Mayaudon, and O. Dupuy
- Subjects
business.industry ,Medicine ,business - Published
- 2014
6. Therapeutic choices in elderly diabetic patients.
- Author
-
Bordier L, Doucet J, and Bauduceau B
- Subjects
- Aged, Humans, Hypoglycemic Agents therapeutic use, Insulin therapeutic use, Comorbidity, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemia chemically induced, Hypoglycemia epidemiology
- Abstract
The care of elderly diabetic patients has now become a real public health issue due to the increase in the number of patients. In this population, complications are more serious and are intertwined with more specifically gerontological issues. Treatment goals should be individualized based on the patient's clinical presentation. New therapeutic drug classes are particularly interesting because of their effectiveness in terms of cardiovascular and renal protection, but the risk/benefit ratio needs to be well assessed on an individual basis. Insulin therapy is often necessary, either in case of failure of oral antidiabetics or because of comorbidities, particularly in the event of renal failure. Educating the patient and family early in the course of the disease is one of the keys to effective and safe treatment. The management of elderly diabetic patients must avoid both too much laxity in those who have successfully aged and unreasonable activism in fragile subjects because of the risk of hypoglycemia., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
7. Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes.
- Author
-
Le Pen C, Bauduceau B, Ansolabehere X, Troubat A, Bineau S, Ripert M, and Dejager S
- Subjects
- Consumer Behavior economics, Cost-Benefit Analysis, Dipeptidyl-Peptidase IV Inhibitors economics, Drug Costs, France, Germany, Glucagon-Like Peptide-1 Receptor antagonists & inhibitors, Humans, Hypoglycemic Agents supply & distribution, Italy, Sodium-Glucose Transporter 2 Inhibitors economics, Spain, United Kingdom, Commerce, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents economics
- Abstract
Background: Different countries have their own systems for evaluating new medicines, and they make decisions as to when and how each new medicine is adopted., Purpose: To compare the rate of uptake of new diabetes medicines (dipeptidyl peptidase-4 inhibitors [DPP-4Is], glucagon-like peptide-1 receptor agonists [GLP1-RAs], and sodium-glucose co-transporter-2 inhibitors [SGLT2Is]) in the five most populated European countries., Methods: The monthly volume of sales of antidiabetic drugs was extracted for each country from the IQVIA™ MIDAS® database for the period 2007 to 2016 and the defined daily doses (DDDs) were calculated. For each new drug, market shares were expressed as a percentage of the total market of non-insulin antidiabetic agents., Results: Sharp differences were observed between the countries. Overall, the highest and fastest rates of uptake were seen for Germany and Spain, compared to lower rates for the UK and Italy. This was especially marked for DPP-4Is, where the market share reached over 30% of non-insulin antidiabetic drugs in Germany and Spain, compared to around 10% in the UK and Italy. In France, there was an initial rapid uptake, which stabilized at around 20% after three years. Rates of uptake were lower for the other drugs, with the GLP1-RAs reaching a market share of 2.5-4.5% in Germany, Spain and France, compared to less than 2.5% in the UK and Italy. The SGLT2Is reached a market share of 5-8% in Spain and Germany, compared to less than 4% in the UK and Italy, and they were not launched at all in France in March 2020., Conclusion: The differences in the uptake of new antidiabetic drugs may reflect different methods for assessing and introducing new medicines, as well as cultural factors. The uptake of the new medicines would appear to be more cautious in the UK and Italy, perhaps due to concerns about cost-effectiveness, whereas in Germany and Spain, and possibly also France, a new medicine's potential benefits may be prioritized., (Copyright © 2021 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
8. Primary care management of non-institutionalized elderly diabetic patients: The S.AGES cohort - Baseline data.
- Author
-
Bucher S, Bauduceau B, Benattar-Zibi L, Bertin P, Berrut G, Corruble E, Danchin N, Delespierre T, Derumeaux G, Doucet J, Falissard B, Forette F, Hanon O, Ourabah R, Pasquier F, Piedvache C, Pinget M, Ringa V, and Becquemont L
- Subjects
- Age Factors, Aged, Aged, 80 and over, Biomarkers blood, Blood Glucose drug effects, Blood Glucose metabolism, Comorbidity, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 epidemiology, Female, France epidemiology, Geriatric Assessment, Glycated Hemoglobin metabolism, Humans, Hypoglycemic Agents adverse effects, Life Style, Male, Prospective Studies, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Diabetes Mellitus, Type 2 drug therapy, Health Services for the Aged, Hypoglycemic Agents therapeutic use, Independent Living, Primary Health Care methods
- Abstract
Aim: S.AGES is a multicenter prospective cohort study of non-institutionalized patients aged 65 and over with atrial fibrillation, type 2 diabetes or chronic pain. Its objective is to describe the medical management in primary care. This article presents the baseline characteristics of subjects in the diabetes subcohort and compares the results to those from cohorts of older diabetic patients., Methods: From April 2009 to June 2011, 983 patients were included in the diabetes subcohort by 213 primary care providers. Demographic data, geriatric parameters and the history, characteristics and treatment of the diabetes were recorded at baseline., Results: The mean age was 76.7 ± 5.9 years. Most patients were living independently, with no cognitive impairment and in relatively good health. The duration of diabetes was 11.3 ± 8.7 years with average HbA1c of 6.9 ± 1.0%. 20% of patients had macrovascular disease, 33% renal failure, 14.6% ocular complication and 7.1% neuropathy. The first-line antidiabetic treatment was metformin (61.2%) and 18% of patients had used insulin. Treatment intensified with the worsening of diabetic symptoms. When compared to those from French and North American cohorts, the results showed increased complications and use of insulin with age, disease duration and severity., Conclusion: Due to the method of recruitment, S.AGES patients were generally healthy with well-controlled diabetes. However, the results were consistent with those from other cohorts. Three-year follow-up is expected to study the management of diabetic patients aged 65 and over in primary care., (Copyright © 2014 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
9. Orthostatic hypotension is associated with more severe hypertension in elderly autonomous diabetic patients from the French Gerodiab study at inclusion.
- Author
-
Bouhanick B, Meliani S, Doucet J, Bauduceau B, Verny C, Chamontin B, and Le Floch JP
- Subjects
- Aged, Aged, 80 and over, Amputation, Surgical, Antihypertensive Agents therapeutic use, Blood Pressure, Blood Pressure Determination, Body Mass Index, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 physiopathology, Female, Follow-Up Studies, France epidemiology, Geriatric Assessment, Humans, Hypertension drug therapy, Hypertension epidemiology, Hypertension physiopathology, Hypotension, Orthostatic drug therapy, Hypotension, Orthostatic epidemiology, Hypotension, Orthostatic physiopathology, Male, Prevalence, Prognosis, Prospective Studies, Risk Factors, Waist-Hip Ratio, Aging, Diabetes Mellitus, Type 2 complications, Hypertension complications, Hypotension, Orthostatic complications, Self Care
- Abstract
Unlabelled: Orthostatic hypotension (OH) has deleterious effects on patients' cardiovascular prognoses. The combination of increased age and diabetes adds to the risk of OH. The aim of the study was to describe the elderly diabetic population relative to the degree of hypertension, the occurrence of complications, medications and cognitive function., Methods: In the Gerodiab study (a 5-year French multicentre, prospective, observational study), a total of 987 type 2 diabetic autonomous patients, aged 77±5 years, were recruited between June 2009 and July 2010. Clinical blood pressure measurements were taken supine and then after 1, 3 and 5minutes in a standing position. OH was defined as a decrease in systolic blood pressure (SBP) of at least 20mmHg and/or a decrease in diastolic blood pressure (DBP) of at least 10mmHg at any of the measurements while standing., Results: At inclusion 301 (30.5%) patients had OH; SBP and DBP at rest were higher in patients with OH than in those without (146±21/78±11mmHg vs. 138±17/72±10mmHg; P<0.001). Individuals with OH exhibited higher pulse pressure (PP) than individuals without (68±18 vs. 65±15mmHg; P<0.05). A significant increase in waist-to-hip ratio was recorded in those with OH versus patients without (P<0.01). Despite more severe hypertension (SBP>160mmHg at inclusion; P<0.01), no significant difference was recorded in the mean number of antihypertensive drugs (1.7±1.1), or in the class of antihypertensive drugs, including beta-blockers (P=0.19) and diuretics (P=0.84). Patients with OH were more likely to have a history of peripheral arterial disease and amputations (31% vs. 24%, P<0.05, and 3.3% vs. 1.5%, P=0.056). There was no significant association between OH and history of peripheral neuropathy (P=0.37), stroke, heart failure or ischemic heart disease. In multivariate analysis, OH remained associated with severe hypertension (P<0.01), increased waist-to-hip ratio (P<0.05) and amputations (P<0.05)., Conclusion: About one-third of elderly, autonomous diabetic patients had OH. They had more severe hypertension, with higher SBP, DBP and PP at rest. However, the number of anti-hypertensive drugs did not differ compared to patients without OH. This could reflect the medical teams' fears about intensifying treatment., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
10. Do published ADA studies support the ADA-EASD position statement for the management of hyperglycaemia in type 2 diabetics?
- Author
-
Rimareix F and Bauduceau B
- Subjects
- Choice Behavior, Consensus, Decision Making, Diabetes Mellitus, Type 2 complications, Drug Therapy, Combination methods, Europe, Humans, Hyperglycemia etiology, Hypoglycemic Agents therapeutic use, Metformin therapeutic use, Risk Reduction Behavior, Societies, Medical, United States, Diabetes Mellitus, Type 2 therapy, Hyperglycemia therapy, Practice Guidelines as Topic
- Abstract
The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement in 2012 on the management of hyperglycaemia in patients with type 2 diabetes. The Société Francophone du Diabète (SFD) adopted it while awaiting future French recommendations. This new care approach individualises the therapeutic choices and objectives for each patient based on their characteristics, through emphasis on the need for mutual cooperation with the patient in decision-making. Glycaemic management should naturally be considered in the context of overall cardiovascular risk reduction, which should remain the primary objective of treatment. The cornerstone of this treatment is based on lifestyle modifications, with the addition of metformin monotherapy if the desired glycaemic control is not attained. There are multiple second- and third-line treatment possibilities, and insulin therapy is an option that can be considered early in the bitherapy stage. On the whole, large published studies at the ADA conference in Philadelphia in June 2012, which are the subject of this article, support this patient-centred position statement., (Copyright © 2013 Elsevier Masson SAS. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
11. [Fourteenth National meeting for residents in endocrinology].
- Author
-
Bauduceau B
- Subjects
- Adolescent, Adolescent Health Services standards, Diabetes Mellitus therapy, Diabetic Nephropathies complications, Diabetic Nephropathies therapy, Endocrinology methods, Endocrinology standards, France, Hirsutism therapy, Humans, Puberty, Delayed therapy, Quality of Health Care, Religion and Medicine, Renal Insufficiency, Chronic complications, Endocrinology organization & administration, Internship and Residency organization & administration, Students, Medical
- Published
- 2013
- Full Text
- View/download PDF
12. [Thyroid metastasis of kidney cancer].
- Author
-
Baïzri H, Bordier L, Garcia C, Gaëtan G, De Kérangal X, Durand X, Dupuy O, Bauduceau B, and Mayaudon H
- Subjects
- Aged, Humans, Male, Carcinoma, Renal Cell secondary, Kidney Neoplasms pathology, Thyroid Neoplasms secondary
- Abstract
Thyroid metastasis of solid tumors is rare and often asymptomatic. Differential diagnosis with malignant thyroid tumor is difficult. We report a 65-year-old man who presented with a solitary intrathoracic thyroid nodule of the left lobe, inaccessible to fine needle biopsy. His past medical history was remarkable for a nephrectomy for a kidney clear cell carcinoma one year before. The PET-scan did not show any abnormal fixation. A left lobo-isthmectomy was performed. Histologic examination revealed an intrathyroid metastasis of kidney carcinoma., (Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
13. [Twelfth national meeting of residents in endocrinology].
- Author
-
Bauduceau B
- Subjects
- Congresses as Topic, Internship and Residency, Endocrinology
- Published
- 2011
- Full Text
- View/download PDF
14. [Hyperparathyroidism during pregnancy: dangerous association for the mother and her infant].
- Author
-
Dupuy O, Aubert P, Dumuis ML, Bordier L, Mayaudon H, and Bauduceau B
- Subjects
- Adult, Calcium blood, Female, Humans, Hypercalcemia etiology, Hyperparathyroidism complications, Infant, Newborn, Parathyroid Neoplasms complications, Pregnancy, Pregnancy Trimester, Third, Reference Values, Treatment Outcome, Hyperparathyroidism diagnosis, Parathyroid Neoplasms surgery, Pregnancy Complications diagnosis
- Abstract
Hypercalcaemia during pregnancy is rare but requires a systematic approach for its diagnosis and its treatment. We report a 32-year-old pregnant female at 32 weeks of gestation who presented a severe hypercalcaemia, due to primary hyperparathyroidism. The delivery allowed the birth of a healthy child who had a serum calcium level in the normal range. Eight days later, the mother was operated from a parathyroid adenoma allowing normalisation of calcaemia. Hyperparathyroidism during pregnancy is rarely reported; it can lead to severe complications for both the mother and the infant. The newborn can present tetania due to hypocalcaemia and hypoparathyroidism can be definitive. Surgery should be discussed when serum calcium level of the mother is markedly elevated., (Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
15. [Uncommon complication of anticoagulant therapy: pituitary hemorrhage].
- Author
-
Dupuy O, Bordier L, Galzin A, Le Berre JP, Mayaudon H, and Bauduceau B
- Subjects
- Aged, 80 and over, Female, Humans, Adenoma complications, Anticoagulants adverse effects, Hemorrhage chemically induced, Pituitary Diseases chemically induced, Pituitary Neoplasms complications
- Abstract
Pituitary apoplexy is well known as the first manifestation of pituitary tumour. Conversely, haemorrhage of a pituitary adenoma, revealed by anticoagulant therapy, is very uncommon. Two weeks after initiation of anticoagulant therapy for a deep venous thrombosis, an 83-year-old woman presented with intracranial hypertension and blindness. CT-scan revealed pituitary hematoma within a large adenoma. Three months after surgery, partial visual defect persisted in association with panhypopituitarism. When pituitary disorder is known, hemorrhage risk should be taken into account in the prescription of anticoagulant therapy., (Copyright (c) 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
16. [Type 2 diabetes mellitus associated with pancreatic and renal malformations].
- Author
-
Le Berre JP, Bellanné-Chantelot C, Bordier L, Garcia C, Dupuy O, Mayaudon H, and Bauduceau B
- Subjects
- Biomarkers metabolism, Female, Genetic Counseling, Humans, Middle Aged, Mutation, Phenotype, Diabetes Mellitus, Type 2 genetics, Hepatocyte Nuclear Factor 1-beta genetics, Kidney abnormalities, Pancreas abnormalities
- Abstract
A 55-year-old woman presented with a recent diabetes mellitus associated with pancreatic and renal malformations. This atypical diabetes raised the possibility of maturity onset diabetes of the young (MODY) and a genetic research was performed. These malformations led to MODY5 diagnosis that was confirmed by the presence of HNF1beta gene mutation., (Copyright 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
17. [Acromegaly in the elderly].
- Author
-
Dupuy O, Petrossians P, Brue T, Morange I, Bordier L, Mayaudon H, and Bauduceau B
- Subjects
- Acromegaly complications, Aged, Aged, 80 and over, Body Mass Index, Diabetes Complications blood, Diabetes Complications epidemiology, Female, France epidemiology, Heart Diseases blood, Heart Diseases epidemiology, Human Growth Hormone blood, Humans, Insulin-Like Growth Factor I metabolism, Male, Reference Values, Registries, Vascular Diseases blood, Vascular Diseases epidemiology, Acromegaly epidemiology
- Abstract
Unlabelled: Multicentric registers such as The French Acromegaly Register provide data on rare disorders that are otherwise difficult to obtain, so avoiding extrapolation from limited data sets. This study focuses on clinical, hormonal and therapy characteristics of acromegaly in people over 70 years old. The objective was to compare this population with the youngest to disclose if the medical management was similar., Patients and Methods: The data were obtained from the 30 centres that have registered patients in the Acromegaly Register since 1999., Results: The register listed 644 acromegaly patients on 1st January 2005, of whom 68 (22 men and 46 women) were over 70 years old, independently of the diagnosis date of their disease. Their average age was 76.8 + or - 5 years (range: 70-95) and they had suffered from acromegaly for 11 + or - 6 years (compared to 7 years in those aged less than 70). Their BMI were similar. Diabetes and hypertension were more frequent than in younger acromegalic patients and in the general French population matched for age. Circulating GH and IGF-1 concentrations were lower than in the younger acromegalic patients on inclusion and 1 year after treatment. There was no significant difference in the tumor size. Only 44% of the patients over 70 underwent surgery, against 90% of patients under 70 years. However, the fractions of young and elderly patients with a controlled disease 1 year after inclusion were the same (51%)., Conclusion: In the limits of the use of register, these data reveal a high prevalence of diabetes and hypertension in the eldest acromegalic patients. Despite much less frequent surgical intervention, patients' disease under control is equivalent to the younger population 1 year after the initial interview, confirming the effectiveness of the choices of treatment.
- Published
- 2009
- Full Text
- View/download PDF
18. Glycaemic control and cardiovascular morbi-mortality: the contribution of the 2008 studies.
- Author
-
Cugnet-Anceau C and Bauduceau B
- Subjects
- Diabetes Mellitus blood, Diabetic Angiopathies epidemiology, Diabetic Angiopathies mortality, Homeostasis, Humans, Hyperglycemia complications, Blood Glucose metabolism, Cardiovascular Diseases epidemiology, Cardiovascular Diseases mortality
- Abstract
The year 2008 was rich in teachings and suspense in diabetology. Past studies, i.e. United Kingdom Prospective Diabetes Study (UKPDS) in type 2 diabetic patients and Diabetes Control and Complications Trial (DCCT) in type 1 diabetic patients, have shown that in the short term, intensive treatment reduces the incidence of microvascular complications linked to diabetes and in the long term that of both microvascular and macrovascular ones. The in-the-raw conclusions of the recent Action to Control Cardiovascular risk in Diabetes (ACCORD) study note an increase in mortality in type 2 diabetic patients treated intensively, while the Action in Diabetes and Vascular disease, Perindopril and Indapamide Controlled Evaluation (ADVANCE) study evidences a reduction in microvascular complications and the Veterans Affairs Diabetes Trial (VADT) study shows that intensive treatment has no significant effect. A well thought-out analysis of the studies published in 2008 (ACCORD, STENO 2 post-trial, ADVANCE, VADT, UKPDS post-trial, Epidemiology of Diabetes Interventions and Complications [EDIC]) is particularly instructive and highlights the existence of glycaemic memory, the non-existence of blood pressure memory, the need to control all cardiovascular risk factors and to treat diabetes early while avoiding hypoglycaemic incidents. The glycaemic target based on HbA1c must take into account the patient's age and the duration of his diabetes, as well as his cardiovascular risk factors and previous glycaemic control. All in all, the intensive treatment of type 2 diabetes must begin early; it must not be too rapid and must avoid hypoglycaemic incidents and be combined with a strict control of other cardiovascular risk factors.
- Published
- 2009
- Full Text
- View/download PDF
19. [Seizure and Bourneville tuberous sclerosis: think about insulinoma].
- Author
-
Le Berre JP, Bey Boeglin M, Duverger V, Garcia C, Bordier L, Dupuy O, Mayaudon H, and Bauduceau B
- Subjects
- Adult, Humans, Hypoglycemia complications, Hypoglycemia etiology, Male, Insulinoma diagnosis, Pancreatic Neoplasms diagnosis, Seizures etiology, Tuberous Sclerosis complications
- Abstract
Bourneville tuberous sclerosis is a phacomatosis characterized by skin, neurological and ophthalmological lesions. At first, seizure can reveal cerebral lesions, but other causes may be suspected. We report a case of a Bourneville tuberous sclerosis in a 41-year-old-man with hypoglycemia leading to seizures, resulting from an insulinoma.
- Published
- 2009
- Full Text
- View/download PDF
20. [Nelson's syndrome management: current knowledge].
- Author
-
Garcia C, Bordier L, Garcia-Hejl C, Ceppa F, Mayaudon H, Dupuy O, and Bauduceau B
- Subjects
- Adolescent, Adrenocorticotropic Hormone biosynthesis, Cushing Syndrome complications, Cushing Syndrome surgery, Cyproheptadine therapeutic use, Diagnosis, Differential, Female, Histamine H1 Antagonists therapeutic use, Humans, Nelson Syndrome diagnosis, Nelson Syndrome etiology, Adrenalectomy adverse effects, Nelson Syndrome drug therapy
- Abstract
Purpose: Nelson's syndrome is a severe complication of bilateral adrenalectomy performed in the treatment of some Cushing's diseases, and its management remains difficult. Trough the observation of a patient suffering from a severe form of Nelson's syndrome for more than 10 years, the authors review the literature and discuss the main current therapeutic possibilities., Current Knowledge and Key Points: Many molecules have been used with variable results. In our observation cabergoline at 2 mg per week seems to be efficient after a 3 and a half years follow-up, in accordance with some recent publications. More than bromocriptine, this dopamine agonist provides interesting prospects for this disease's management. Moreover, if the conventional treatments as valproic acid or cyproheptadine are not very efficient, somatostatin analogs seem to be of some therapeutic interest., Future Prospects and Projects: New molecules are currently evaluated, but studies are difficult to conduct because of the low disease prevalence. Tumour receptors analysis undoubtedly constitutes an attractive way to find new therapeutic targets.
- Published
- 2007
- Full Text
- View/download PDF
21. [Craniopharyngiomas: role of radiotherapy].
- Author
-
Chargari C, Bauduceau O, Bauduceau B, Camparo P, Ceccaldi B, Fayolle M, Le Moulec S, and Védrine L
- Subjects
- Age Factors, Craniopharyngioma complications, Craniopharyngioma surgery, Humans, Neoplasm, Residual radiotherapy, Pituitary Neoplasms complications, Pituitary Neoplasms surgery, Radiotherapy Dosage, Tumor Burden, Craniopharyngioma radiotherapy, Pituitary Neoplasms radiotherapy
- Abstract
Craniopharyngiomas are benign tumors of the parasellar region, characterised by high relapsing rate. Aggressive attempt at total removal does result in prolonged progression-free survival in most patients. But for tumors that clearly involve the hypothalamus, complications associated with radical surgery have prompted to adopt a combined strategy of conservative surgery and radiation therapy to residual tumor with an as high rate of cure. This strategy seems to offer the best long-term control rates with acceptable morbidity. But optimal management of craniopharyngiomas remains controversial. Although it is generally recommended that radiotherapy is given following sub-total excision of a craniopharyngioma, it remains unclear as to whether all patients with residual tumour should receive immediate or differed at relapse radiotherapy.
- Published
- 2007
22. [Silent thyroiditis in a patient under lithium therapy].
- Author
-
Garcia C, Mayaudon H, Dupuy O, Le Berre JP, Bordier L, and Bauduceau B
- Subjects
- Humans, Male, Middle Aged, Antimanic Agents adverse effects, Hypothyroidism chemically induced, Lithium Carbonate adverse effects
- Abstract
While hypothyroidism secondary to treatments by lithium are well known, cases of hyperthyroidism are less common. A 48 years old patient under lithium carbonate from about 10 years ago presents hyperthyroidism without any auto-immunity biological markers, associated with a very low thyroid tracer uptake on scintigraphy. Treatments by anti thyroid agents will be necessary during months in order to normalize the hormone level, whereas lithium is maintained. Only few tens of cases of hyperthyroidism related to lithium have been reported in the literature. This observation shows the importance of the thyroid hormonal follow up for patients under lithium, in order to treat them before the outbreak of a thyroid dysfunction. The causal toxic mechanism is still unclear, and may be related with a direct damage of lithium to follicular cells.
- Published
- 2007
- Full Text
- View/download PDF
23. [Pasteurella dagmatis spondylodiscitis in a diabetic patient].
- Author
-
Dupuy O, Garrabé E, Bordier L, Boyer B, Goasguen O, Mayaudon H, and Bauduceau B
- Subjects
- Animals, Dogs, Humans, Male, Middle Aged, Pasteurella Infections transmission, Thoracic Vertebrae, Toes injuries, Animals, Domestic microbiology, Diabetes Mellitus, Type 2 complications, Discitis microbiology, Pasteurella isolation & purification, Pasteurella Infections complications
- Abstract
Introduction: Healthy pets contact are able to induce unusual and severe diseases., Clinical Case: This case reports the medical history of a dorsal spondylodiscitis in a diabetic patient admitted for a chronic wound of his toes. He had a long-standing history of regular consumption of alcohol and tobacco. Blood bottles and biopsy of intervertebral disc infected discovered Pasteurella dagmatis, commonly colonizing the oropharynx of healthy dogs and cats. In this case, licking of his injured toe by his dog was the likely source of entry of the organism., Discussion: We found no identical cases in the medical literature. Diabetes mellitus and other immunocompromised disorders justify to change behaviours toward domestic animals.
- Published
- 2006
- Full Text
- View/download PDF
24. [Is mild hyperhomocysteinemia an additional risk factor of the metabolic syndrome?].
- Author
-
Garcin JM, Mayaudon H, Bauduceau B, Abouzahir A, Burnat P, Gardet V, Bordier L, Dupuy O, and Baigts F
- Subjects
- Adult, Blood Glucose metabolism, Blood Pressure, Cholesterol blood, Cross-Sectional Studies, France epidemiology, Homocysteine blood, Humans, Hyperhomocysteinemia blood, Insulin blood, Male, Metabolic Syndrome blood, Middle Aged, Risk Factors, Triglycerides blood, Hyperhomocysteinemia complications, Metabolic Syndrome epidemiology
- Abstract
Introduction: Metabolic syndrome is a cardiovascular risk factors cluster and hyperhomocysteinemia an obvious independant risk factor., Objective: To ascertain if hyperhomocysteinemia is associated with the metabolic syndrome., Methods: "Epimil" is a prospective epidemiologic survey, which began by a cross-sectionnal study of cardiovascular risk factors in a French population, which then will be followed for ten years for supervision and intervention. Initial data collection, blood pressure measurement, ECG and blood samples (biology and DNA) have been performed. For the metabolic syndrome, we used the criterias of the third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (NCEP ATP III)., Results: Out of 2045 men aged from 20 to 58 years (37.7+/-8.7 years), 185 (9%) have metabolic syndrome (at least three criterias), 587 (29%) a blood homocysteine>or=12 micromol/L and 202 (10%)>or=15 micromol/L. Homocysteinemia is 10.97+/-5.01 micromol/L for the whole population and doesn't differ with (11.4+/-6 micromol/L) or without (10.9+/-5 micromol/L) the metabolic syndrome, as does its values distribution. It's not correlate with the body mass index, waist and hip measurements, nor with glycemia, HbA1c, insulin resistance and cardiovascular risk markers (CRPus, microalbuminuria). It weakly correlates with systolic and diastolic blood pressure, creatinine clearance, tobacco use, cholesterolemia, triglycerides and free fatty acids but not with HDL and LDL fractions, nor lipoprotein (a). Among this population, it slightly contributes to the ten years vascular risk evaluated according to Framingham equations or Score system., Conclusions: Homocysteinemia and the prevalence of hyperhomocysteinemia don't differ with or without the metabolic syndrome and doesn't correlate its main criterias.
- Published
- 2005
- Full Text
- View/download PDF
25. [Unusual evolution of autoimmune hypothyroidism: occurrence of Grave's disease].
- Author
-
Le Berre JP, Rousseau C, Dupuy O, Bordier L, Mayaudon H, and Bauduceau B
- Subjects
- Adult, Aged, Female, Graves Disease blood, Graves Disease diagnosis, Graves Disease drug therapy, Humans, Immunoglobulins, Thyroid-Stimulating blood, Male, Thyroiditis, Autoimmune blood, Thyroiditis, Autoimmune diagnosis, Thyroiditis, Autoimmune drug therapy, Treatment Outcome, Graves Disease etiology, Thyroid Hormones blood, Thyroiditis, Autoimmune complications, Thyrotropin blood
- Published
- 2004
- Full Text
- View/download PDF
26. [Extreme obesity in Prader-Willi Syndrome (PWS)].
- Author
-
Damiano J, Ficko C, Garrabé E, Mayaudon H, Dupuy O, Carmoi T, Bordier L, and Bauduceau B
- Subjects
- Adult, Body Height, Female, Genetic Testing, Human Growth Hormone therapeutic use, Humans, Obesity, Morbid pathology, Prader-Willi Syndrome diagnosis, Prader-Willi Syndrome genetics, Chromosomes, Human, Pair 15, Obesity, Morbid etiology, Prader-Willi Syndrome complications
- Abstract
Introduction: Prader-Willi Syndrome (PWS) belong to genetic obesities and we report a caricatural observation., Development: The early onset of (PWS) is characterised by a severe neonatal hypotonia with poor suck reflex--which may lead to tube feeding--and poor weight gain. Later appears insatiable appetite, morbid obesity associated with short stature, dysmorphic syndrome with small hands and behavioural disorders. Although diagnosis is based on clinical features, it must be confirmed by genetic test looking for the characteristic deletion of the chromosome 15q11-q13 region. PWS is the first example in humans of genetic imprinting., Conclusion: Today, the challenge in PWS is it early management which may authorise Growth Hormone administration.
- Published
- 2003
- Full Text
- View/download PDF
27. [Suspicious adrenal glands].
- Author
-
Dupuy O, Bordier L, Dolz M, Mayaudon H, Hauret L, Vergos M, and Bauduceau B
- Subjects
- Adenocarcinoma diagnosis, Adrenal Gland Diseases diagnosis, Adrenal Gland Neoplasms diagnosis, Diagnosis, Differential, Humans, Hydrocortisone blood, Male, Middle Aged, Tomography, X-Ray Computed, Adenocarcinoma secondary, Adrenal Gland Neoplasms secondary, Gastrointestinal Neoplasms pathology
- Published
- 2002
- Full Text
- View/download PDF
28. [Unmeasurable uric acid in blood and urine; xanthine dehydrogenase deficiency (or hereditary xanthinuria)].
- Author
-
Mayaudon H, Bauduceau B, Dupuy O, Ceppa F, Roul G, and Burnat P
- Subjects
- Adult, Chromosome Mapping, Chromosomes, Human, Pair 2, Female, Humans, Male, Mutation, Purine-Pyrimidine Metabolism, Inborn Errors genetics, Purine-Pyrimidine Metabolism, Inborn Errors urine, Uric Acid urine, Xanthine Dehydrogenase genetics, Purine-Pyrimidine Metabolism, Inborn Errors blood, Uric Acid blood, Xanthine urine, Xanthine Dehydrogenase deficiency
- Published
- 1999
- Full Text
- View/download PDF
29. [Castleman disease and solitary plasmacytoma of the acromion].
- Author
-
Dupuy O, Dourthe LM, Mayaudon H, Ceccaldi B, Lechevalier D, Gros P, Gessain A, and Bauduceau B
- Subjects
- Follow-Up Studies, Humans, Immunoglobulin G analysis, Immunoglobulin lambda-Chains analysis, Male, Middle Aged, Acromion pathology, Bone Neoplasms complications, Castleman Disease complications, Plasmacytoma complications
- Published
- 1999
- Full Text
- View/download PDF
30. [Serratia odorifera biovar 1 bronchial infection].
- Author
-
Ceccaldi B, Cariou B, Soullié B, Le Berre JP, Mayaudon H, Dupuy O, and Bauduceau B
- Subjects
- Aged, Aged, 80 and over, Anti-Infective Agents therapeutic use, Bronchoalveolar Lavage Fluid microbiology, Ciprofloxacin therapeutic use, Diabetes Mellitus, Type 2 complications, Humans, Immunocompromised Host, Male, Serratia classification, Bronchial Diseases microbiology, Serratia Infections diagnosis
- Published
- 1999
- Full Text
- View/download PDF
31. [A new case of acute hepatitis type E in France].
- Author
-
Dupuy O, Mayaudon H, Bauduceau B, Perrier E, Nizou C, Pottier V, and Buisson Y
- Subjects
- Acute Disease, Aged, Cholestasis virology, France, Hepatitis Antibodies analysis, Hepatitis E virus immunology, Humans, Immunoglobulin M analysis, Jaundice virology, Male, Hepatitis E diagnosis
- Published
- 1998
- Full Text
- View/download PDF
32. [Prolactinoma and pregnancy. Six cases and review of the literature].
- Author
-
Helie C, Mayaudon H, Bauduceau B, Riveline JP, Ducorps M, Ponties JE, and Charles G
- Subjects
- Adult, Breast Feeding, Delivery, Obstetric, Female, Humans, Pituitary Neoplasms epidemiology, Pregnancy, Pregnancy Complications, Neoplastic epidemiology, Prenatal Care, Prognosis, Prolactinoma epidemiology, Risk Factors, Pituitary Neoplasms therapy, Pregnancy Complications, Neoplastic therapy, Prolactinoma therapy
- Abstract
Prolactinoma is the most frequent of secreting pituitary adenomas. It is often discovered among women of childbearing-age presenting an association of amenorrhea and galactorrhea. Data in the literature from large series indicate the current risks of interaction between prolactinoma and pregnancy. Risks have been overestimated in the past and it is now recognized that pregnancy can be allowed providing strict follow-up is assured. Dopaminergic drugs have no teratogenic side-effects and are known to allow tumoral control and recovery of fertility in the majority of cases. The use of these medications explains the reduction of indications for surgery. Microprolactinomas are highly influenced by pregnancy and can even lead to tumor retrogression. Macroprolactinomas give complications more often, and require a good tumor control and a rigorous follow-up.
- Published
- 1996
33. [Prolactin response to protirelin in reactive arthritis and ankylosing spondyloarthritis. Failure of treatment of 4 reactive arthritis with bromocriptine].
- Author
-
Eulry F, Bauduceau B, Bouée S, Crozes P, Magnin J, Mayaudon H, and Lechevalier D
- Subjects
- Adult, Arthritis, Reactive blood, Humans, Male, Prolactin blood, Thyrotropin-Releasing Hormone pharmacology, Arthritis, Reactive drug therapy, Bromocriptine therapeutic use, Spondylitis, Ankylosing blood
- Published
- 1994
34. [Action of trandolapril on the blood glucose balance and microalbuminuria in hypertensive diabetics].
- Author
-
Bauduceau B, Vaur L, Rezvani Y, and Gautier D
- Subjects
- Aged, Angiotensin-Converting Enzyme Inhibitors pharmacology, Diabetes Mellitus, Type 2 metabolism, Female, Humans, Hypertension etiology, Hypertension metabolism, Indoles pharmacology, Male, Middle Aged, Albuminuria drug therapy, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Blood Glucose metabolism, Diabetes Mellitus, Type 2 complications, Diabetic Angiopathies drug therapy, Hypertension drug therapy, Indoles therapeutic use
- Abstract
The aim of this study was to evaluate the action of trandolapril on blood glucose control and microalbuminuria in mild to moderate hypertensive in patients with non-insulin-dependent diabetes. Sixty-seven patients, aged between 33 and 79, were enrolled. After a two week placebo run-in period, treatment with trandolapril as monotherapy was given for 3 months. The dose of trandolapril was adjusted between 1 and 4 mg/day according to antihypertensive response. Patients were assessed clinically and by laboratory investigations each month. Two patients were excluded from efficacy analysis because of major protocol deviations. Mean DBP fell, under the influence of treatment, from 101 +/- 5 mmHg to 82 +/- 7 mmHg (p < 0.0001) and mean SBP from 171 +/- 9 mmHg tp 147 +/- 11 mmHG (p < 0.0001). At three months, 54 patients (84%) had a DBP < or = 90 mmHg. Microalbuminuria decreased significantly (p = 0.03) during treatment. Microalbuminuria returned to normal in 11 of the 13 patients in whom the baseline value was above 21 micrograms/min and increased to above normal in 2 of the 26 patients who had a normal baseline value. Blood glycosylated hemoglobin, fructosamine, glucose and creatinine, and creatinine clearance remained stable. Plasma potassium rose slightly in 7 patients. Six adverse events were reported (4 coughs, 1 peripheral edema, 1 plantar mal perforans). One patient died from pulmonary embolism. In conclusion, trandolapril is an effective antihypertensive agent in hypertensive diabetics. Trandolapril causes a significant decrease in microalbuminuria and does not interfere with blood glucose control in these patients.
- Published
- 1994
35. [Early spinal bone loss in Klinefelter syndrome. X-ray computed tomographic evaluation in 16 cases].
- Author
-
Eulry F, Bauduceau B, Lechevalier D, Magnin J, Flageat J, and Gautier D
- Subjects
- Adolescent, Adult, Bone Density, Bone Resorption diagnostic imaging, Case-Control Studies, Estradiol blood, Humans, Klinefelter Syndrome blood, Lumbar Vertebrae, Male, Osteoporosis diagnostic imaging, Osteoporosis prevention & control, Testosterone blood, Testosterone therapeutic use, Absorptiometry, Photon, Bone Resorption etiology, Klinefelter Syndrome complications, Osteoporosis etiology
- Abstract
The lumbar spine bone density (BMD) was assessed by single energy quantitative tomography in 16 young patients with non traited Klinefelter's syndrome (19 +/- 2.2 yr) and in 16 age weight- and height-matched control males. The BMD were significantly lower in the patients than in the control group (175 +/- 26 mg/cm3 K2HPO4 vs 204 +/- 26; p < 0.02). The authors found a significant correlation between BMD and plasmatic levels of testosterone and estradiol suggesting the hormonal origin of the osteopenia whereas no correlation was found with serum calcium, phosphorus or prolactin levels or hydroxy-proteinuria. Such osteopenia in young patients with Klinefelter's syndrome supports early androgenic treatment of these patients.
- Published
- 1993
36. [Hormonal profile of idiopathic gynecomastia in young adults. Apropos of 488 cases].
- Author
-
Bauduceau B, Reboul P, Le Guyadec T, Legrelle M, Mayaudon H, and Gautier D
- Subjects
- Adolescent, Adult, Chorionic Gonadotropin pharmacology, Cohort Studies, Gonadotropin-Releasing Hormone pharmacology, Gynecomastia epidemiology, Humans, Male, Thyrotropin-Releasing Hormone pharmacology, Dihydrotestosterone blood, Estradiol blood, Gynecomastia blood, Testosterone blood
- Abstract
Gynecomastia, a very frequent disorder, is present in almost 40% of young men. In this population the investigations often fail to find any aetiology, therefore defining idiopathic gynecomastia. The aim of this work is to compare clinical and hormonal characteristics of 488 subjects with gynecomastia to 41 healthy controls. Their are many explanations for the occurrence of idiopathic gynecomastia, including modification of hormonal balance, change of aromatase activity, or a receptor anomaly. Our works demonstrate a significant decrease in mean testosteronemia, linked to a high prevalence of incipient hypogonadism in the studied population, especially in patients with an history of testicular disease.
- Published
- 1993
37. [Arthritis and palmoplantar pustulosis].
- Author
-
Bauduceau B, Hanny P, Chanudet X, Celton H, Doury P, and Larroque P
- Subjects
- Aged, Arthritis diagnosis, Female, Humans, Suppuration, Arthritis etiology, Foot Dermatoses complications, Hand Dermatoses complications
- Abstract
Pustulosis palmaris et plantaris may be associated with a number of articular diseases. Known to be present in Fiessinger-Leroy-Reiter syndrome and psoriasis arthropatica, this skin disease has been classified by Japanese authors as a new nosological entity: pustular osteo-arthritis. Pustulosis palmaris et plantaris seems to represent a meeting point for axial rheumatisms close to ankylozing spondylitis.
- Published
- 1987
- Full Text
- View/download PDF
38. [Digital microembolism disclosing intracardiac thrombosis].
- Author
-
Chanudet X, Clément R, Brunetti G, Ollivier JP, Bauduceau B, Celton H, and Larroque P
- Subjects
- Adult, Embolism diagnosis, Embolism therapy, Humans, Male, Embolism etiology, Fingers blood supply, Heart Diseases complications, Thrombosis complications
- Abstract
The authors report the observation of a 46 year old man with a case history of myocardial infarction at the age of 26 years, transient ischemic injury at 41 years of age, and in whom a focalised digital ischemic syndrome of microembolic nature led to the discovery of an intracardial thrombosis which was operated upon and progressed without complication. Bloody microembolisms of cardiac origin may be selectively revealed by acrosyndromes, the diagnostic elements of which are mentioned. They are poorly understood conditions. Their significance must not be neglected because of the risk of recurrence in macroembolic form. The pathogenesis of these obstructions and their specific responsibility for ischemic cardiopathies is reviewed. It is appropriate to emphasise the novelty of this observation since, in the context of ischemic cardiopathies, no attention has been devoted to microembolisms, in contrast to the numerous publications relating to macroembolisms. The symptomatic treatment is unremarkable, the etiological treatment of intracardial thrombosis is discussed.
- Published
- 1986
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.